FDA Issues More Guidance Regarding Distribution of Reprints. Is It "Fair and Balanced?"
FDA seems obsessed with the distribution of reprints by the pharmaceutical industry.In January, 2009, FDA "finalized" its "Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices U.S." (see "FDA Finalizes Guidance on Distribution of Reprints").That guidance, however, was not well-received by the pharma industry and in February, 2014, the agency released a new draft guidance document entitled "Distributing Scientific and Medical Publications on U...
Source: Pharma Marketing Blog - June 10, 2014 Category: Pharma Commentators Tags: Drug Safety FDA Guidance off-label promotion side effects Source Type: blogs
Pharma "Insiders": Change Enemies or Back Stabbers?
My friend Rich Meyer, author of World of DTC Marketing Blog, once again has gone on a rant. This time his target is pharma "insiders.""One of the reasons that pharma marketing has been in a funk is the simple fact that there is a lack of people who are willing to change processes to focus on patients," Meyer says. "Instead, most pharma people are too busy attending meaningless meetings from morning till night and trying to 'get along' with others rather than rock a boat that very much needs rocking. My personal belief is that most pharma executives are afraid to hire smarter people than th...
Source: Pharma Marketing Blog - June 5, 2014 Category: Pharma Commentators Tags: Social Media Pioneer Award Source Type: blogs
Globally, Pharma's Digital Spend is (Still) Only 6% of Total Promotional Budget
According to Cegedim Strategic Data (CSD) -- a provider of healthcare promotional audits -- in the last 6 months of 2013, the global pharma industry spent nearly $2.5 billion on all digital channels including pharma company websites, social media, web banner advertising in professional online journals and mobile apps.That works out to be approximately 6% of the total audited marketing expenditure, which includes "traditional, personal promotional channels;" i.e., sales reps.NOTE: I am uncertain if this CSD audit includes direct-to-consumer (DTC) promotional spending, which is only legal in the U.S. Also, keep i...
Source: Pharma Marketing Blog - June 4, 2014 Category: Pharma Commentators Tags: Cegedim Digital Pharma ePromotion marketing mix Source Type: blogs
WLF to FDA Regarding Distribution of Off-Label Reprints: See You in Court!
In February 2014, FDA released a new draft guidance document entitled "Distributing Scientific and Medical Publications on Unapproved New Uses - Recommended Practices." FDA's revised guidance is aimed at addressing some of industry's and the public's concerns regarding the previous guidelines by making clear that the pharmaceutical and medical device industries can distribute medical and scientific reprints -- including reprints of studies for new and unapproved uses of drugs -- to medical professionals, but only under certain conditions.In public comments submitted to FDA, the Washington Legal Foun...
Source: Pharma Marketing Blog - June 3, 2014 Category: Pharma Commentators Tags: FDA Guidance guidelines off-label promotion Reprints Source Type: blogs
Healthcare Marketers Trend Report 2014: I Give It a "C-Meh!" Rating
"Not all available market research is created equal," says Rich Meyer, author of DTC Marketing Blog. According to Meyer, "some research is a must have and provides insights, but there is also a lot of available research that doesn’t clarify findings and is written by journalists not people will real world pharma business experience." He goes on to rate various sources of pharma marketing research (here).Meyer has two ratings:"A-Must Have" and "D-Pass," which means don't bother with it. Meyer doesn't have a "C-Meh!" rating -- that's my way of saying "lackl...
Source: Pharma Marketing Blog - June 2, 2014 Category: Pharma Commentators Tags: Market Research marketing mix Media Mix Source Type: blogs
Pharma DTC Advertising Spend vs. Time Consumers Spend in Various Media
I came upon an interesting chart in Mary Meeker’s state-of-the-Internet slide deck. Meeker — formerly of Morgan Stanley, at VC firm Kleiner Perkins since late 2010 — each year produces a curated set of data reflecting what she sees as the major trends in Internet usage and growth. The chart (below) shows how American attention is divided among various forms of media and how that division lines up with where advertising dollars go, as I learned here. Click on chart for an enlarged view.I assume that the Ad Spending data reflect the average for all industries in the U.S. and the Time Spent in Media reflects what the av...
Source: Pharma Marketing Blog - May 29, 2014 Category: Pharma Commentators Tags: Ad Spend DTC Advertising Source Type: blogs
WikiCorrect-Health - Who, Who Are You! Who, who, who, who? 'Cause I really wanna know.
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - March 24, 2014 Category: Pharma Commentators Tags: Ethics social media transparency Wikipedia Source Type: blogs
Annual Pharma Investment in "eSales," "eDetailing," "Virtual Detailing" … Whatever!
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - March 21, 2014 Category: Pharma Commentators Tags: eDetailing Sales and Sales Reps Virtual Detailing Source Type: blogs
Pharma Spends What on eSales?
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - March 17, 2014 Category: Pharma Commentators Tags: eSampling Sales and Sales Reps Source Type: blogs
Why the FDA Approved Zohydro
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - March 17, 2014 Category: Pharma Commentators Tags: Drug Safety FDA Legal/Regulatory Source Type: blogs
Red GOP States Addled by Adderall
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - March 12, 2014 Category: Pharma Commentators Tags: Adderall ADHD Source Type: blogs
FDA's "Crimean Referendum" Putsched Aveed Through the Approval Process
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - March 7, 2014 Category: Pharma Commentators Tags: Aveed FDA Legal/Regulatory Low T testosterone Source Type: blogs
Lipitor Down, But Not Out: Pfizer Plans an OTC Version. Will It Benefit or Harm Consumers?
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - March 3, 2014 Category: Pharma Commentators Tags: generics Lipitor OTC Pfizer Source Type: blogs
The Sarah Palin of Pharma: Former Novartis Executive in Japan Says Docs are Masters, Drugmakers are Slaves
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - February 28, 2014 Category: Pharma Commentators Tags: Diddies and Spoofs Source Type: blogs
FDA Wakes Up to Social Media's Ability to Monitor Drug Adverse Events
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - February 27, 2014 Category: Pharma Commentators Tags: Adverse events FDA social media Source Type: blogs
